First insights into the safety and effectiveness of additional courses with cladribine tablets under real-world conditions
Administering additional cladribine courses is an effective option to maintain disease control and did not trigger any serious adverse events attributable to the therapy. Patients with elevated serum transaminase levels should be regularly monitored.
Authors
- Christoph Kleinschnitz (ORCID: https://orcid.org/0000-0002-1650-8875)
- Lukas Cepek
- Refik Pul (ORCID: https://orcid.org/0000-0002-8940-9317)
- Matthias Schwab (ORCID: https://orcid.org/0000-0002-9984-075X)
- Benedicta Kühnler
- Markus C. Kowarik (ORCID: https://orcid.org/0000-0003-1389-5539)
- Jelena Škuljec (ORCID: https://orcid.org/0000-0001-8509-6563)
- Sylke Schlemilch-Paschen
- Michael Ernst
- Lara Woitschach
- Daniela Rau
Institutions
- Universität Ulm (DE)
- Essen University Hospital (DE)
- Jena University Hospital (DE)
- Hertie Institute for Clinical Brain Research (DE)
- Klinik und Poliklinik für Psychiatrie und Psychotherapie (DE)
- University Hospital Ulm (DE)
- Zentrum für Pathologie und Zytodiagnostik (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1016/j.msard.2025.106398
- Citations
- 5
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 8.13
Funders
- Merck KGaA